A Solid Dispersion of Quercetin Shows Enhanced Nrf2 Activation and Protective Effects against Oxidative Injury in a Mouse Model of Dry Age-Related Macular Degeneration.
Animals
Eye Proteins
/ genetics
Female
Gene Expression Regulation
/ drug effects
Gene Expression Regulation, Enzymologic
/ drug effects
Macular Degeneration
/ genetics
Mice
Mice, Knockout
NF-E2-Related Factor 2
/ genetics
Oxidation-Reduction
/ drug effects
Oxidoreductases
/ biosynthesis
Quercetin
/ pharmacology
Rats
Rats, Sprague-Dawley
Reactive Oxygen Species
/ metabolism
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
05
2019
accepted:
17
09
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
21
4
2020
Statut:
epublish
Résumé
Age-related macular degeneration (AMD) represents a major reason for blindness in the elderly population. Oxidative stress is a predominant factor in the pathology of AMD. We previously evaluated the effects of phospholipid complex of quercetin (Q-PC) on oxidative injury in ARPE-19 cells, but the underlying mechanisms are not fully understood. Herein, the solid dispersion of quercetin-PC (Q-SD) was prepared with solubility being 235.54
Identifiants
pubmed: 31781321
doi: 10.1155/2019/1479571
pmc: PMC6875405
doi:
Substances chimiques
Eye Proteins
0
NF-E2-Related Factor 2
0
Nfe2l2 protein, mouse
0
Reactive Oxygen Species
0
Quercetin
9IKM0I5T1E
Oxidoreductases
EC 1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1479571Informations de copyright
Copyright © 2019 Yan Shao et al.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3164-77
pubmed: 16799064
Arch Ophthalmol. 2001 Oct;119(10):1439-52
pubmed: 11594943
PLoS One. 2011 Apr 29;6(4):e19456
pubmed: 21559389
Oxid Med Cell Longev. 2016;2016:4378461
pubmed: 27656262
Biochem Pharmacol. 2012 Jan 1;83(1):6-15
pubmed: 21856292
Acta Pharm Sin B. 2014 Feb;4(1):18-25
pubmed: 26579360
Eur J Pharm Sci. 2015 Oct 12;78:103-10
pubmed: 26165620
Annu Rev Biochem. 2017 Jun 20;86:715-748
pubmed: 28441057
J Pharm Pharmacol. 2006 Sep;58(9):1227-33
pubmed: 16945181
Curr Drug Discov Technol. 2012 Mar;9(1):17-24
pubmed: 21644920
Am J Ophthalmol. 2019 May 15;:
pubmed: 31100217
Drug Dev Ind Pharm. 2015;41(10):1693-703
pubmed: 25496311
Drug Dev Ind Pharm. 2015 May;41(5):772-9
pubmed: 24669978
J Pharm Pharmacol. 2008 Sep;60(9):1121-9
pubmed: 18718114
JAMA Ophthalmol. 2019 Apr 1;137(4):372-379
pubmed: 30676617
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Crit Rev Clin Lab Sci. 2015 Feb;52(1):12-27
pubmed: 25319011
Free Radic Res. 2010 Nov;44(11):1267-88
pubmed: 20815789
Curr Med Chem. 2013;20(20):2572-82
pubmed: 23514412
Eur J Pharmacol. 2016 Jan 5;770:1-8
pubmed: 26643168
Clin Ophthalmol. 2015 Apr 01;9:563-74
pubmed: 25878491
J Biol Chem. 2009 May 15;284(20):13291-5
pubmed: 19182219
Toxicol Appl Pharmacol. 2006 Apr 15;212(2):110-8
pubmed: 16126241
Invest Ophthalmol Vis Sci. 2006 Feb;47(2):729-37
pubmed: 16431974
J Food Sci. 2008 Aug;73(6):C500-5
pubmed: 19241541
Mol Aspects Med. 2012 Aug;33(4):399-417
pubmed: 22510306
J Ophthalmol. 2013;2013:862806
pubmed: 24163760
Dev Ophthalmol. 2014;53:1-32
pubmed: 24732758
Proc Nutr Soc. 2017 Aug;76(3):175-181
pubmed: 27903318